Menu
  • Join
  • Login
  • Contact
 

Search abstracts


EFFICACY AND SAFETY ASESSMENT OF GENERIC AND BRAND-NAME DRUG ROSUVASTATIN IN DYSLIPIDEMIA MANAGEMENT

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: CHUNG, Ming-Chieh (Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Department of Pharmacy, China Taiwan)
  • Co-author(s): Ming-Chieh Chung: Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, China Taiwan
    Hui-Qi Liu: Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, China Taiwan
  • Abstract:

    Background

    Generic drugs are therapeutic equivalent to their brand-name drugs. However, some may concern generic drugs do not work as well as brand-name drugs. Many reports indicated genetic rosuvastatin may not be equivalent to brand-name drugs (CRESTOR®) in treating hyperlipidemia.

    Methods

    We did a retrospective study from Jan. 2015 to Dec. 2017. In

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses